Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia

Y. Kawai, K. Watanabe, M. Kizaki, Mitsuru Murata, Tetsuji Kamata, H. Uchida, T. Moriki, K. Yokoyama, M. Tokuhira, H. Nakajima, M. Handa, Y. Ikeda

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Treatment of acute promyelocytic leukemia (APL) patients with all-trans retinoic acid (ATRA) was associated with rapid improvement in hemostatic markers. We made serial analyses of various hemostatic parameters in seven newly diagnosed APL patients. In all patients at diagnosis, plasma fibrinogen/fibrin degradation product (fragment-E), cross-linked fibrin degradation product (D-dimer fragment), thrombin-antithrombin III complex and plasmin-α2-plasmin inhibitor complex were elevated, indicating the presence of disseminated intravascular coagulation (DIC). Antithrombin III (ATIII) levels were normal in all patients except for the patient with congenital ATIII deficiency. In four patients subsequently treated with ATRA without anticoagulant therapy, these hemostatic markers returned to near-normal levels by day 7 of treatment, indicating that DIC was essentially resolved. By contrast, in three patients who received conventional chemotherapy with a continuous low-dose heparin, improvement of coagulopathy was slower than in patients treated with ATRA. These results suggest that ATRA therapy exerts the rapid improvement in abnormal hemostatic markers in APL patients without any anticoagulant therapies, by inducing differentiation of leukemic cells and, in turns no massive release of procoagulant or fibrinolytic substances from these cells.

Original languageEnglish
Pages (from-to)184-188
Number of pages5
JournalAmerican Journal of Hematology
Volume46
Issue number3
DOIs
Publication statusPublished - 1994

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Hemostatics
Fibrin Fibrinogen Degradation Products
Disseminated Intravascular Coagulation
Anticoagulants
Antithrombin III Deficiency
Therapeutics
Antithrombin III
Heparin
Cell Differentiation
Drug Therapy

Keywords

  • acute promyelocytic leukemia
  • all-trans retinoic acid
  • coagulopathy
  • disseminated intravascular coagulation
  • hemostatic markers
  • heparin therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia. / Kawai, Y.; Watanabe, K.; Kizaki, M.; Murata, Mitsuru; Kamata, Tetsuji; Uchida, H.; Moriki, T.; Yokoyama, K.; Tokuhira, M.; Nakajima, H.; Handa, M.; Ikeda, Y.

In: American Journal of Hematology, Vol. 46, No. 3, 1994, p. 184-188.

Research output: Contribution to journalArticle

Kawai, Y, Watanabe, K, Kizaki, M, Murata, M, Kamata, T, Uchida, H, Moriki, T, Yokoyama, K, Tokuhira, M, Nakajima, H, Handa, M & Ikeda, Y 1994, 'Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia', American Journal of Hematology, vol. 46, no. 3, pp. 184-188. https://doi.org/10.1002/ajh.2830460305
Kawai, Y. ; Watanabe, K. ; Kizaki, M. ; Murata, Mitsuru ; Kamata, Tetsuji ; Uchida, H. ; Moriki, T. ; Yokoyama, K. ; Tokuhira, M. ; Nakajima, H. ; Handa, M. ; Ikeda, Y. / Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia. In: American Journal of Hematology. 1994 ; Vol. 46, No. 3. pp. 184-188.
@article{190b56b943584caf81122c01ecc887cb,
title = "Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia",
abstract = "Treatment of acute promyelocytic leukemia (APL) patients with all-trans retinoic acid (ATRA) was associated with rapid improvement in hemostatic markers. We made serial analyses of various hemostatic parameters in seven newly diagnosed APL patients. In all patients at diagnosis, plasma fibrinogen/fibrin degradation product (fragment-E), cross-linked fibrin degradation product (D-dimer fragment), thrombin-antithrombin III complex and plasmin-α2-plasmin inhibitor complex were elevated, indicating the presence of disseminated intravascular coagulation (DIC). Antithrombin III (ATIII) levels were normal in all patients except for the patient with congenital ATIII deficiency. In four patients subsequently treated with ATRA without anticoagulant therapy, these hemostatic markers returned to near-normal levels by day 7 of treatment, indicating that DIC was essentially resolved. By contrast, in three patients who received conventional chemotherapy with a continuous low-dose heparin, improvement of coagulopathy was slower than in patients treated with ATRA. These results suggest that ATRA therapy exerts the rapid improvement in abnormal hemostatic markers in APL patients without any anticoagulant therapies, by inducing differentiation of leukemic cells and, in turns no massive release of procoagulant or fibrinolytic substances from these cells.",
keywords = "acute promyelocytic leukemia, all-trans retinoic acid, coagulopathy, disseminated intravascular coagulation, hemostatic markers, heparin therapy",
author = "Y. Kawai and K. Watanabe and M. Kizaki and Mitsuru Murata and Tetsuji Kamata and H. Uchida and T. Moriki and K. Yokoyama and M. Tokuhira and H. Nakajima and M. Handa and Y. Ikeda",
year = "1994",
doi = "10.1002/ajh.2830460305",
language = "English",
volume = "46",
pages = "184--188",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia

AU - Kawai, Y.

AU - Watanabe, K.

AU - Kizaki, M.

AU - Murata, Mitsuru

AU - Kamata, Tetsuji

AU - Uchida, H.

AU - Moriki, T.

AU - Yokoyama, K.

AU - Tokuhira, M.

AU - Nakajima, H.

AU - Handa, M.

AU - Ikeda, Y.

PY - 1994

Y1 - 1994

N2 - Treatment of acute promyelocytic leukemia (APL) patients with all-trans retinoic acid (ATRA) was associated with rapid improvement in hemostatic markers. We made serial analyses of various hemostatic parameters in seven newly diagnosed APL patients. In all patients at diagnosis, plasma fibrinogen/fibrin degradation product (fragment-E), cross-linked fibrin degradation product (D-dimer fragment), thrombin-antithrombin III complex and plasmin-α2-plasmin inhibitor complex were elevated, indicating the presence of disseminated intravascular coagulation (DIC). Antithrombin III (ATIII) levels were normal in all patients except for the patient with congenital ATIII deficiency. In four patients subsequently treated with ATRA without anticoagulant therapy, these hemostatic markers returned to near-normal levels by day 7 of treatment, indicating that DIC was essentially resolved. By contrast, in three patients who received conventional chemotherapy with a continuous low-dose heparin, improvement of coagulopathy was slower than in patients treated with ATRA. These results suggest that ATRA therapy exerts the rapid improvement in abnormal hemostatic markers in APL patients without any anticoagulant therapies, by inducing differentiation of leukemic cells and, in turns no massive release of procoagulant or fibrinolytic substances from these cells.

AB - Treatment of acute promyelocytic leukemia (APL) patients with all-trans retinoic acid (ATRA) was associated with rapid improvement in hemostatic markers. We made serial analyses of various hemostatic parameters in seven newly diagnosed APL patients. In all patients at diagnosis, plasma fibrinogen/fibrin degradation product (fragment-E), cross-linked fibrin degradation product (D-dimer fragment), thrombin-antithrombin III complex and plasmin-α2-plasmin inhibitor complex were elevated, indicating the presence of disseminated intravascular coagulation (DIC). Antithrombin III (ATIII) levels were normal in all patients except for the patient with congenital ATIII deficiency. In four patients subsequently treated with ATRA without anticoagulant therapy, these hemostatic markers returned to near-normal levels by day 7 of treatment, indicating that DIC was essentially resolved. By contrast, in three patients who received conventional chemotherapy with a continuous low-dose heparin, improvement of coagulopathy was slower than in patients treated with ATRA. These results suggest that ATRA therapy exerts the rapid improvement in abnormal hemostatic markers in APL patients without any anticoagulant therapies, by inducing differentiation of leukemic cells and, in turns no massive release of procoagulant or fibrinolytic substances from these cells.

KW - acute promyelocytic leukemia

KW - all-trans retinoic acid

KW - coagulopathy

KW - disseminated intravascular coagulation

KW - hemostatic markers

KW - heparin therapy

UR - http://www.scopus.com/inward/record.url?scp=0028263780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028263780&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830460305

DO - 10.1002/ajh.2830460305

M3 - Article

C2 - 8192147

AN - SCOPUS:0028263780

VL - 46

SP - 184

EP - 188

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -